Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector
2006; Oxford University Press; Volume: 194; Issue: 12 Linguagem: Inglês
10.1086/509258
ISSN1537-6613
AutoresAndrew Catanzaro, Richard A. Koup, Mario Roederer, Robert T. Bailer, Mary E. Enama, Zoe Moodie, Lin Gu, Julie E. Martin, Laura Novik, Bimal K. Chakrabarti, Bryan T. Butman, Jason G. Gall, C. Richter King, Charla Andrews, Rebecca Sheets, Phillip L. Gomez, John R. Mascola, Gary J. Nabel, Barney S. Graham,
Tópico(s)Herpesvirus Infections and Treatments
ResumoThe development of an effective human immunodeficiency virus (HIV) vaccine is a high global priority. Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine.
Referência(s)